Epigenetics: A New Approach for the Treatment of Multiple Myeloma

LONDON, December 15, 2016 /PRNewswire/ --

Andrew Spencer, Sridurga Mithraprabhu, European Oncology & Haematology, 2016;12(2):96-102 DOI: https://doi.org/10.17925/EOH.2016.12.02.96

     (Logo: http://photos.prnewswire.com/prnh/20151014/276718LOGO )

Published recently in European Oncology & Haematology Review, the peer-reviewed journal from touchONCOLOGY, Andrew Spencer et al, highlights the critical need for more effective therapies in multiple myeloma (MM) since all patients eventually relapse following front-line treatment. A variety of both genetic and epigenetic abnormalities may be present in MM, the latter including DNA and histone methylation and histone deacetylation, and are thought to contribute to the pathogenesis of the disease. For example, global methylation analysis in MM has identified inactivated tumour suppressor genes that are prognostically important. Through their ability to acetylate histones and cytoplasmic proteins, histone deacetylases (HDAC) influence a wide variety of cellular functions, such as proliferation, differentiation and apoptosis. Increased class 1 HDAC expression has been linked in solid tumours with more locally advanced, de-differentiated and proliferative tumours, and with poor prognosis in MM. HDAC inhibitors, panobinostat and ricolinostat, have been demonstrated to be effective in combination with bortezomib and dexamethasone in newly diagnosed patients with MM and in heavily pre-treated patients with advanced MM. HDAC inhibitor-monoclonal antibody combinations are also being explored. The potential of HDAC inhibitors to improve outcome for patients with MM is evident but a greater understanding of their anti-tumour effects is needed.

The full peer-reviewed, open-access article is available here:

https://doi.org/10.17925/EOH.2016.12.02.96    

Disclosure: Andrew Spencer and Sridurga Mithraprabhu have nothing to disclose in relation to this article. This study involves a review of the literature and did not involve any studies with human or animal subjects performed by any of the authors.

Note to the Editor

touchONCOLOGY (a division of Touch Medical Media) publishes

European Oncology & Haematology Review, a peer-reviewed, open access, bi-annual journal specialising in the publication of balanced and comprehensive review articles written by leading authorities to address the most important and salient developments in the field of oncology and haematology. The aim of these reviews is to break down the high science from 'data-rich' primary papers and provide practical advice and opinion on how this information can help physicians in the day to day clinical setting. Practice guidelines, symposium write-ups, case reports, and original research articles are also featured to promote discussion and learning amongst physicians, clinicians, researchers and related healthcare professionals.

http://www.touchONCOLOGY.com

For inquires please contact:
Nicola Cartridge - Managing Editor
[email protected]
T: +44-(0)207-193-3186
Providing practical opinion to support best practice for busy healthcare professionals.

SOURCE touchONCOLOGY.com